What is Roth Capital’s Forecast for MBRX Q1 Earnings?

Moleculin Biotech, Inc. (NASDAQ:MBRX) – Research analysts at Roth Capital issued their Q1 2025 earnings per share estimates for shares of Moleculin Biotech in a research note issued to investors on Thursday, November 14th. Roth Capital analyst J. Aschoff anticipates that the company will earn ($1.26) per share for the quarter. The consensus estimate for Moleculin Biotech’s current full-year earnings is ($8.60) per share. Roth Capital also issued estimates for Moleculin Biotech’s Q2 2025 earnings at ($1.25) EPS, Q3 2025 earnings at ($1.25) EPS and Q4 2025 earnings at ($1.25) EPS.

MBRX has been the subject of a number of other research reports. StockNews.com initiated coverage on shares of Moleculin Biotech in a research note on Wednesday, November 13th. They set a “sell” rating for the company. Maxim Group reduced their price objective on Moleculin Biotech from $20.00 to $8.00 and set a “buy” rating for the company in a research report on Tuesday, November 12th.

Moleculin Biotech Stock Performance

MBRX stock opened at $2.52 on Monday. The firm has a 50 day simple moving average of $2.52 and a 200 day simple moving average of $3.28. Moleculin Biotech has a 52 week low of $2.12 and a 52 week high of $15.75.

Institutional Investors Weigh In On Moleculin Biotech

A hedge fund recently raised its stake in Moleculin Biotech stock. Armistice Capital LLC grew its position in Moleculin Biotech, Inc. (NASDAQ:MBRX) by 5.1% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 156,000 shares of the company’s stock after purchasing an additional 7,505 shares during the quarter. Armistice Capital LLC owned approximately 6.75% of Moleculin Biotech worth $549,000 as of its most recent SEC filing. Institutional investors own 15.52% of the company’s stock.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.